Yukta marra (Fever of unknown origin) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Yukta Marra, more commonly referred to in the medical literature as Fever of Unknown Origin (FUO), is a clinical syndrome characterized by a prolonged fever (≥ 38.3 °C or 101 °F) that persists for at least three weeks and remains undiagnosed after an initial outpatient or hospital evaluation. The term “yukta marra” is used in some South‑Asian traditional medicine texts, but the modern definition follows criteria set by the classic 1961 Petersdorf & Beeson description and later updates by the Infectious Diseases Society of America (IDSA).

FUO can affect anyone, but epidemiological patterns show:

• Adults (≥ 18 years): 70–80 % of cases.
• Children and adolescents: 20–30 % of cases, often related to different etiologies (e.g., autoinflammatory diseases).
• Incidence: Approximately 5–10 cases per 100,000 hospital admissions in high‑income countries; data from low‑resource settings are sparse but likely under‑reported.

Because the fever’s cause remains hidden, the evaluation often requires a multidisciplinary approach that includes infectious disease specialists, rheumatologists, oncologists, and sometimes psychiatrists.

Symptoms

While the hallmark is unexplained fever, many patients present with additional systemic signs that can provide diagnostic clues. The following list groups symptoms by organ system and includes brief descriptions.

General

• Fever – Persistent, daily spikes; may be higher in the evening.
• Night sweats – Drenching perspiration that soaks clothing or bedding.
• Weight loss – Unintentional loss of > 5 % body weight over weeks to months.
• Fatigue / malaise – Profound tiredness not relieved by rest.
• Chills / rigors – Intense shivering episodes often preceding a temperature rise.

Cardiovascular

• Palpitations
• Chest discomfort (rare, may suggest endocarditis or lymphoma)

Respiratory

• Cough (dry or productive)
• Dyspnea or shortness of breath
• Hemoptysis (rare, points toward TB or granulomatous disease)

Gastrointestinal

• Abdominal pain or discomfort
• Nausea / vomiting
• Diarrhea or constipation
• Hepatosplenomegaly (enlarged liver or spleen)

Genitourinary

• Dysuria or urinary frequency
• Pelvic or flank pain (possible occult pyelonephritis)

Neurologic

• Headache (often dull, may be throbbing)
• Confusion or altered mental status (often late sign)
• Seizures (very rare, usually linked to CNS infection or vasculitis)

Dermatologic

• Rash (maculopapular, petechial, or erythema nodosum)
• Lymphadenopathy – enlarged, sometimes tender lymph nodes

Causes and Risk Factors

FUO is a diagnostic umbrella. Causes are classically divided into four categories: Infections, Malignancies, Connective‑tissue/autoimmune diseases, and “Miscellaneous” (including drug fever, factitious fever, and endocrine disorders). Below is a concise breakdown with the most common culprits in each group.

Infectious

• Tuberculosis (especially extrapulmonary) – 10–20 % of FUO cases in endemic areas.<sup>1</sup>
• Subacute bacterial endocarditis
• Deep‑seated abscesses (e.g., psoas, hepatic)
• Fungal infections (histoplasmosis, coccidioidomycosis, cryptococcosis)
• Viral infections (CMV, EBV, HIV seroconversion, hepatitis)
• Parasitic diseases (malaria, leishmaniasis, toxoplasmosis)

Malignancies

• Lymphoma (especially Hodgkin’s and diffuse large B‑cell) – up to 15 % of adult FUO.
• Leukemia
• Renal cell carcinoma
• Hepatocellular carcinoma
• Metastatic solid tumors

Connective‑tissue / Autoimmune

• Systemic lupus erythematosus (SLE)
• Adult‑onset Still’s disease
• Rheumatoid arthritis (especially with vasculitis)
• Granulomatosis with polyangiitis (Wegener’s)
• Sarcoidosis

Miscellaneous

• Drug‑induced fever (e.g., antibiotics, antiepileptics, allopurinol)
• Factitious fever (self‑induced, often in psychiatric settings)
• Thyrotoxicosis
• Deep‑venous thrombosis with associated inflammation (e.g., septic thrombophlebitis)
• Idiopathic hyper‑IgE syndrome

Risk Factors

Factors that increase the likelihood of developing FUO include:

• Immunosuppression – HIV infection, transplant recipients, chemotherapy.
• Travel or residence in endemic regions for TB, malaria, or zoonotic infections.
• Chronic indwelling devices (central venous catheters, prosthetic heart valves).
• Unexplained weight loss or cachexia.
• Age > 65 years – higher risk for malignancy‑related FUO.

Diagnosis

Diagnosing FUO is a stepwise, systematic process that balances thoroughness with cost‑effectiveness. The classical approach consists of three phases: history & physical examination → focused laboratory & imaging studies → advanced investigations.

1. Detailed History & Physical

• Chronology of fever (pattern, spikes, relation to meals, travel).
• Exposure history – animal contact, insect bites, occupational hazards.
• Medication review – prescription, over‑the‑counter, herbal supplements.
• Vaccination and immunization status.
• Family history of autoimmune disease or malignancy.

2. Initial Laboratory Panel

Complete blood count (CBC) with differential

Erythrocyte sedimentation rate (ESR) & C‑reactive protein (CRP)

Comprehensive metabolic panel (CMP) – liver & kidney function

Urinalysis & urine culture

Blood cultures (at least 2 sets, drawn > 1 hour apart)

Serologic screens: HIV, hepatitis B/C, CMV, EBV, toxoplasma IgG/IgM

Autoimmune panel: ANA, rheumatoid factor, anti‑CCP, ANCA

Ferritin, lactate dehydrogenase (LDH), and uric acid

3. Imaging

• Chest X‑ray – first‑line for pulmonary sources.
• Abdominal ultrasound – evaluates hepatosplenomegaly, abscesses.
• CT scan (chest/abdomen/pelvis) – higher sensitivity for occult masses, lymphadenopathy, and deep infections.
• 18F‑FDG PET/CT – increasingly valuable; highlights hypermetabolic foci that guide biopsy.<sup>2</sup>

4. Specialized Tests

• Bone marrow aspiration/biopsy – indicated when hematologic malignancy is suspected.
• Lumbar puncture – if neurologic signs or meningitis are possible.
• Echo‑cardiography (transthoracic, then transesophageal if suspicion of endocarditis remains).
• Bronchoscopy with BAL (bronchoalveolar lavage) for pulmonary infiltrates.
• Serum cytokine assays (e.g., IL‑6) – adjunct in Still’s disease and some infections.

5. Diagnostic Algorithm (Simplified)

1. Rule out common infections with cultures and basic serology.
2. If negative, proceed to imaging (CT ± PET).
3. Targeted biopsies of any suspicious lesions.
4. Apply rheumatologic and oncologic panels based on imaging/clinical clues.
5. Consider “empiric trial” of antipyretics and observation only after a thorough work‑up if no lead emerges.

According to a 2020 review in *The Lancet Infectious Diseases*, a definitive diagnosis is reached in 70–80 % of FUO cases within the first 3‑4 weeks of investigation when this structured approach is used.<sup>3</sup>

Treatment Options

Treatment hinges on the underlying cause. While awaiting a diagnosis, symptom control and prevention of complications are vital.

Empiric Symptomatic Management

• Antipyretics – Acetaminophen 650 mg PO q6h PRN (avoid NSAIDs if renal failure or active GI bleed).
• Hydration – Intravenous isotonic fluids if oral intake is insufficient.
• Rest and sleep hygiene.
• Nutrition – High‑calorie, high‑protein diet or oral supplements.

Cause‑Specific Therapies

Category	Typical Therapeutic Agents
Infections	Broad‑spectrum antibiotics (e.g., ceftriaxone + vancomycin) pending cultures; specific agents once organism identified – isoniazid + rifampin for TB, amphotericin B for systemic mycoses.
Malignancies	Chemotherapy regimens tailored to histology (e.g., R‑CHOP for diffuse large B‑cell lymphoma), targeted therapies (e.g., rituximab), or surgical resection when feasible.
Autoimmune / Inflammatory	High‑dose corticosteroids (prednisone 1 mg/kg PO daily) followed by steroid‑sparing agents such as methotrexate, azathioprine, or IL‑1 inhibitors (anakinra) for Still’s disease.
Drug fever	Discontinuation of the offending medication; symptoms typically resolve within 48–72 hours.
Factitious fever	Psychiatric evaluation and appropriate mental‑health interventions.

Adjunctive Measures

• Physical cooling measures (cool compresses, tepid sponging).
• Prophylactic anticoagulation (low‑dose LMWH) if prolonged immobilization risk is high.
• Vaccinations – especially pneumococcal and influenza – once the acute phase subsides.

Living with Yukta Marra (Fever of Unknown Origin)

Even after a diagnosis is established, many patients experience chronic or recurrent fevers. Ongoing management focuses on quality of life, monitoring, and self‑care.

Daily Management Tips

• Temperature tracking – Keep a fever diary (time, max temperature, associated symptoms). This helps clinicians spot patterns.
• Medication schedule – Take antipyretics at regular intervals; avoid “stacking” unless directed.
• Hydration – Aim for ≥ 2 L of fluids daily unless fluid‑restricted for cardiac/renal disease.
• Nutrition – Small, frequent meals; include iron‑rich foods if anemia is present.
• Sleep hygiene – Dark, cool bedroom; limit screen time before bed.
• Physical activity – Light walking or stretching as tolerated; avoid over‑exertion during febrile spikes.
• Stress management – Mindfulness, yoga, or counseling can reduce autonomic triggers that may worsen fever.

Follow‑up Schedule

1. First 2 weeks after diagnosis – weekly clinical review or telehealth check.
2. Months 1‑3 – bi‑weekly visits to monitor response to therapy, labs, and side‑effects.
3. Beyond 3 months – monthly or as‑needed based on disease stability.

When to Adjust Treatment

Discuss with your physician if any of the following occur:

• Fever persists > 48 hours despite appropriate therapy.
• New organ involvement (e.g., cough, dyspnea, jaundice).
• Laboratory abnormalities (rising transaminases, worsening cytopenias).
• Significant medication side effects (e.g., steroid‑induced hyperglycemia).

Prevention

Because “unknown origin” implies the causative agent is not yet identified, primary prevention targets the most common categories of FUO.

• Infection control – Hand hygiene, safe food handling, travel vaccinations (e.g., BCG for TB‑endemic travel, yellow fever, hepatitis A).
• Immunization – Keep routine vaccinations up to date, especially influenza, pneumococcal, and COVID‑19 boosters.
• Medical device care – Proper aseptic technique for central lines, catheter changes, and prosthetic valve prophylaxis.
• Medication review – Periodic assessment to discontinue unnecessary drugs that could cause fever.
• Screening in high‑risk groups – Annual TB skin test or IGRA for immunocompromised patients; age‑appropriate cancer screenings (colonoscopy, mammography, low‑dose CT for lung cancer).

Complications

If the underlying cause remains untreated, FUO can lead to serious sequelae:

• Organ damage – Hepatic necrosis from disseminated infection, renal failure from sepsis or drug toxicity.
• Septic shock – Particularly with occult bacteremia or endocarditis.
• Progression of malignancy – Delayed cancer diagnosis worsens stage and reduces survival.
• Autoimmune destruction – Uncontrolled vasculitis may cause permanent vascular injury.
• Psychological impact – Chronic fever can lead to anxiety, depression, or social isolation.
• Medication‑related complications – Long‑term steroids increase risk of osteoporosis, hyperglycemia, and infection.

When to Seek Emergency Care

If you notice any of the following red‑flag signs, go to the nearest emergency department or call emergency services immediately:

• Fever ≥ 40 °C (104 °F) that does not respond to antipyretics.
• Severe headache with neck stiffness (possible meningitis).
• Sudden shortness of breath, chest pain, or palpitations.
• Altered mental status, confusion, or seizures.
• Persistent vomiting or inability to retain fluids for > 24 hours.
• New or worsening rash with purpura or petechiae (possible meningococcemia).
• Unexplained swelling of legs or abdomen suggesting deep‑vein thrombosis or organomegaly with pain.
• Rapidly growing lymph nodes with overlying skin changes.

---

References:
1. World Health Organization. Global Tuberculosis Report 2023.
2. C. Lee et al., “Role of FDG‑PET/CT in Fever of Unknown Origin,” *Radiology*, 2022.
3. A. Swartz, “Approach to Fever of Unknown Origin,” *Lancet Infectious Diseases*, 2020.
Additional guidelines from Mayo Clinic, CDC, and NIH were consulted for symptom and management recommendations.

```